TEKTURNA Trademark

Trademark Overview

On Wednesday, January 7, 2004, a trademark application was filed for TEKTURNA with the United States Patent and Trademark Office. The USPTO has given the TEKTURNA trademark a serial number of 79001021. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Thursday, April 23, 2015. This trademark is owned by Novartis AG. The TEKTURNA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of diseases and disorders of [ the central nervous system, the immune system, ] the cardiovascular system [ , the respiratory system, musculo-skeletal and inflammatory disorders, or for use in dermatology and oncology ]
tekturna

General Information

Serial Number79001021
Word MarkTEKTURNA
Filing DateWednesday, January 7, 2004
Status706 - SECTION 71 ACCEPTED
Status DateThursday, April 23, 2015
Registration Number2951884
Registration DateTuesday, May 17, 2005
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 22, 2005

Trademark Statements

Amendment to a Registration/Renewal CertificateIn the statement, Column 1, lines 7-8, " the central nervous system, the immune system," is deleted In the statement, Column 1, lines 8-12, " , the respiratory system, musculo-skeletal and inflammatory disorders, or for use in dermatology and oncology" is deleted
Goods and ServicesPharmaceutical preparations for the treatment of diseases and disorders of [ the central nervous system, the immune system, ] the cardiovascular system [ , the respiratory system, musculo-skeletal and inflammatory disorders, or for use in dermatology and oncology ]

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 17, 2004
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNoden Pharma DAC
Party Type31 - New Owner After Registration
Legal Entity Type99 - Other
AddressDublin
IE
Party NameNovartis AG
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCH
Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCH
Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCH

Trademark Events

Event DateEvent Description
Tuesday, August 31, 2004NON-FINAL ACTION MAILED
Friday, March 12, 2004SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, March 17, 2004NEW APPLICATION ENTERED
Friday, July 23, 2004ASSIGNED TO EXAMINER
Thursday, September 9, 2004REFUSAL PROCESSED BY IB
Friday, October 1, 2004REFUSAL PROCESSED BY IB
Monday, November 15, 2004PAPER RECEIVED
Tuesday, November 16, 2004TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 17, 2004PAPER RECEIVED
Wednesday, November 17, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 1, 2004AMENDMENT FROM APPLICANT ENTERED
Thursday, December 2, 2004APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 10, 2004ASSIGNED TO LIE
Tuesday, May 17, 2005REGISTERED-PRINCIPAL REGISTER
Monday, December 20, 2004LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, February 2, 2005NOTICE OF PUBLICATION
Tuesday, February 22, 2005PUBLISHED FOR OPPOSITION
Thursday, March 16, 2006FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 7, 2006FINAL DECISION PROCESSED AND SENT TO IB
Wednesday, December 10, 2008TEAS SECTION 7 REQUEST RECEIVED
Tuesday, January 6, 2009ASSIGNED TO PARALEGAL
Wednesday, January 7, 2009AMENDMENT UNDER SECTION 7 - PROCESSED
Saturday, June 27, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 27, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 6, 2010PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, March 26, 2011PARTIAL INVALIDATION PROCESSED BY THE IB
Monday, May 16, 2011TEAS SECTION 71 RECEIVED
Monday, May 16, 2011CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, May 26, 2011REGISTERED-SEC.71 ACCEPTED
Thursday, May 26, 2011REVIEW OF CORRESPONDENCE COMPLETE
Sunday, February 26, 2012PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Saturday, February 23, 2013CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, April 12, 2013NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, May 28, 2013PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Saturday, July 27, 2013PARTIAL INVALIDATION PROCESSED BY THE IB
Thursday, January 23, 2014INTERNATIONAL REGISTRATION RENEWED
Tuesday, April 7, 2015TEAS SECTION 71 RECEIVED
Thursday, April 23, 2015CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, April 23, 2015REGISTERED-SEC.71 ACCEPTED
Thursday, April 23, 2015NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Wednesday, December 23, 2015PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Saturday, February 27, 2016INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Thursday, August 10, 2017CHANGE OF OWNER RECEIVED FROM IB
Tuesday, April 21, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, April 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 21, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 21, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, January 20, 2024NEW REPRESENTATIVE AT IB RECEIVED
Thursday, January 25, 2024INTERNATIONAL REGISTRATION RENEWED
Friday, May 17, 2024COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Tuesday, May 13, 2025TEAS SECTION 71 RECEIVED
Monday, August 11, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, August 15, 2025POST REGISTRATION ACTION MAILED - SEC.71

Related Keywords

tekturna system disorders musculo respiratory skeletal inflammatory dermatology cardiovascular oncology immune